J. Goldman & CO LP Argenx Se Transaction History

J. Goldman & CO LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $869,732 - $1.1 Million	2,443 New	2,443 $1.05 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $1.27 Million - $1.89 Million	3,742 Added 277.19%	5,092 $1.94 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $249,311 - $370,190	675 Added 100.0%	1,350 $663,000
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $243,094 - $285,241	-675 Reduced 50.0%	675 $263,000
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $451,210 - $544,927	1,350 New	1,350 $502,000
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $223,555 - $286,121	-2,961 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $27,017 - $36,157	361 Added 13.88%	2,961 $245,000
Q1 2018 May 15, 2018	SELL	$56.95 - $85.19 $1.3 Million - $1.94 Million	-22,822 Reduced 89.77%	2,600 $209,000
Q4 2017 Feb 16, 2018	BUY	$22.57 - $63.56 $573,774 - $1.62 Million	25,422	25,422 $1.61 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.